David Kabakoff Increases Stake in NXTC
David Kabakoff purchased 3,510 shares of NXTC on June 18, 2026.
Key Points
- David Kabakoff bought 3,510 shares of NXTC on June 18, 2026, with shares trading near $1.75.
- NXTC has been active among institutional investors, with Squadron Capital Management adding 28,034 shares.
- Analysts like Lucid Capital Markets have set a $25 price target on NXTC, maintaining a 'buy' rating.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
David Kabakoff purchased 3,510 shares of NXTC on June 18, 2026. The shares were acquired without a prearranged trading plan, and the transaction was reported as an open-market purchase.
Other Institutional Activity in NXTC
Squadron Capital Management LLC grew its holdings by 28,034 shares, ending with 265,000 shares worth about $2,830,200. Affinity Asset Advisors, LLC reduced its stake by 5,468 shares, bringing its total to 241,826 shares valued at approximately $2,582,702. Ikarian Capital, LLC, Sofinnova Investments, Inc., and SilverArc Capital Management, LLC maintained their positions without changes, holding 238,303, 222,654, and 176,057 shares, respectively. Vanguard Capital Management LLC opened a new position with 160,473 shares, valued at around $1,688,176.
NextCure, Inc. Stock Down 71.3%
Shares of NXTC traded near $1.75 on Tuesday. Despite the low trading price, the company has attracted attention from both insiders and institutional investors, suggesting potential interest in its future performance.
$NXTC stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at NextCure, Inc.
On June 18, 2026, several insiders, including Ellen Feigal, Anne Elizabeth Borgman, Elaine Jones, John Houston, and Stephen Webster, purchased 2,340 shares each of NXTC. These transactions were not made under prearranged trading plans and reflect a coordinated buying effort alongside David Kabakoff's larger purchase.
Analysts Set New Price Targets
On May 11, 2026, Lucid Capital Markets initiated coverage of NXTC with a 'buy' rating and a $25 price target. Ladenburg Thalmann upgraded the stock to a 'buy' with an $18 target on November 7, 2025. Piper Sandler maintained its 'buy' rating with a $15 target on July 15, 2025. HC Wainwright & Co. reiterated a 'buy' rating with a $3 target on July 1, 2025.
Bottom Line
David Kabakoff's recent purchase adds to the growing interest in NXTC among insiders and institutional investors. With analysts maintaining favorable ratings and setting optimistic price targets, the company remains a focus of attention. As always, these trades and ratings reflect past actions and opinions, not current recommendations.
Get NextCure, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NXTC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.